Agrawal, P, Harish, V, Mohd, S, Singh, SK, Tewari, D, Tatiparthi, R, Harshita, Vishwas, S, Sutrapu, S, Dua, K & Gulati, M 2023, 'Role of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies', Life Sciences, vol. 330, pp. 122003-122003.
View/Download from: Publisher's site
Alharbi, KS, Javed Shaikh, MA, Imam, SS, Alshehri, S, Ghoneim, MM, Almalki, WH, Singh, SK, Kumar, D, Kumar, AP, Dua, K, Chellappan, DK, Paudel, KR & Gupta, G 2023, 'Role of Flavonoids in Management of Various Biological Targets in Alzheimer’s Disease: Evidence from Preclinical to Clinical Studies', Current Medicinal Chemistry, vol. 30, no. 18, pp. 2061-2074.
View/Download from: Publisher's site
View description>>
Abstract:More than 10 million people worldwide have Alzheimer's disease (AD), a degenerative neurological illness and the most prevalent form of dementia. AD's progression in memory loss, cognitive deterioration, and behavioral changes are all symptoms. Amyloid-beta 42 (Aβ42), the hyperphosphorylated forms of microtubule-associated tau protein, and other cellular and systemic alterations are all factors that contribute to cognitive decline in AD. Rather than delivering a possible cure, present therapy strategies focus on reducing disease symptoms. It has long been suggested that various naturally occurring small molecules (plant extract products and microbiological isolates, for example) could be beneficial in preventing or treating disease. Small compounds, such as flavonoids, have attracted much interest recently due to their potential to alleviate cellular stress. Flavonoids have been proven helpful in various ways, including antioxidants, anti-inflammatory agents, and anti-apoptotic agents, but their mechanism remains unknown. The flavonoid therapy of Alzheimer's disease focuses on this review, which includes a comprehensive literature analysis.
Alharbi, KS, Singh, Y, Prasad Agrawal, G, Altowayan, WM, Almalki, WH, Sharma, A, Singh, SK, Jha, NK, Chellappan, DK, Dua, K & Gupta, G 2023, 'Synergism of CD28 Immune Molecule in Late Immunosuppressive Phase of COVID-19: Effectiveness in Vaccinated Individuals.', Altern Ther Health Med, vol. 29, no. 3, pp. 67-73.
View description>>
CONTEXT: Lymphopenia has been frequently documented and linked to coronavirus disease 2019 (COVID-19) in a severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) attack. A decrease in the T-lymphocyte count has shown promise as a clinical indicator and predictor of COVID-19 severity. OBJECTIVE: The review intended to examine the relationship of COVID-19 infections in individuals to lost expression of CD28 on naive CD4+/CD8+-mediated, vaccine-specific, neutralizing antibody responses. DESIGN: The research team performed a narrative review by searching eight databases: Medline, Elsevier, Cochrane, PubMed, Google Scholar, Mendeley, and Springer Nature. The search used the following key terms: SARS CoV-2, clinical aspects and pathology of SARS CoV-2, involvement of viral spike (S) protein in SARS CoV-2, immunological changes in COVID-19 infection, basic overview of CD28 immuno-molecule ligand, reduction of vaccine therapeutic efficacy in COVID-19 infection, and immunomodulatory response of lost CD28 ligand. SETTING: This study was done in a Maharishi Arvind College of Pharmacy, Jaipur, India. RESULTS: In COVID-19 patients, particularly those with severe disease, had increased levels of IL-2 or IL-2R. Given IL-2's supportive role in the expansion and differentiation of T cells, the authors exhibiting that lymphopenia, particularly in severe COVID-19, could be attributed to nonfunctional and dysfunctional differentiation of CD4+ and CD8+ T cells as a result of low CD28 immuno-molecule expression on naive T cells. CONCLUSIONS: The literature review found that independent, early immunological prognostic markers for a poor prognosis, in addition to higher levels of IL-6, include a substantial proportion of large inflammatory monocytes and a small proportion of chronic CD28+ CD4+T cells. The current findings suggest that a combination of COVID-19 vaccination with SARS CoV-2-reactive naive T cells with the CD28 immune-molecule may be a viable method for es...
Amador-Fernández, N, Baechler, T, Quintana-Bárcena, P & Berger, J 2023, 'Documentation of drug related problems and their management in community pharmacy: Data evolution over six years', Research in Social and Administrative Pharmacy, vol. 19, no. 11, pp. 1480-1485.
View/Download from: Publisher's site
View description>>
BACKGROUND: Documentation of pharmacists' activities, such as drug related problems (DRPs) management, is necessary to estimate fair remuneration but is rarely done in community pharmacies. OBJECTIVE: To document and evaluate the evolution of DRPs prevalence and management over six years. METHODS: Observational study carried out since 2016 in a community pharmacy. Documentation was made yearly for 21 days (depending on seasons, holidays and medical internship rotations) using the ClinPhADoc tool. Pharmacists documented: medication, DRP type, intervention, implied partner and time for DRP management. A subanalysis was made depending on the medical rotation. RESULTS: A total of 171 437 prescriptions were received and 6 844 (4.0%) documented with 1 550 DRPs. Most frequent DRPs were procedural (n = 506, 32.6%), dosage/posology (n = 263, 17.0%) and drug-drug interaction (n = 153, 9.9%). Mean time dedicated to DRP management was 6.9 min, the longest time was for clinical DRPs (11.0 min, SD = 6.6). Most DRPs (n = 726, 44.6%) were managed by the pharmacist alone taking less working time than when involving other stakeholders (p < 0.01). Statistically significant differences were found in DRPs between the beginning and end of medical rotation (p < 0.05). CONCLUSIONS: Documentation of DRP management allowed consistent results over the years. Patterns of DRPs can be used to develop inter-professional interventions to prevent DRPs.
Amador-Fernández, N, Gastelurrutia, MÁ & García-Cárdenas, V 2023, 'Development of self-care in Spanish community pharmacies', Exploratory Research in Clinical and Social Pharmacy, vol. 12, pp. 100337-100337.
View/Download from: Publisher's site
View description>>
Spain is a European country with over 47.5 million inhabitants and a public National Health System model (i.e., SNS or “Sistema Nacional de Salud”) that provides universal coverage to residents and non-residents. The system is funded primarily by general taxes, and it is managed by the 17 regions that have responsibility for the provision and management of healthcare services in their respective territories. The health system recognizes self-care as an important element where individuals have an important role to play in maintaining their own health and preventing illness. In addition, there are non-governmental organizations that promote self-care and provide resources and support to individuals and health professionals. Over 55 thousand pharmacists work in 22,198 community pharmacies distributed throughout the Spanish territory. Pharmacies are the only setting that provide non-prescription medications, which is one of the most used tools for self-care. In addition, they provide a range of Primary Care services to improve patient outcomes and the efficiency of the SNS. This paper includes a description and a classification of the community pharmacy services following the seven pillars of self-care established by the International Self-Care Foundation: - Related to pillars 1 to 4 and 6, Spanish community pharmacists provide health promotion, health education, health information and nutritional assessment. - In relation to pillar 5, the services offered are HIV and syphilis screening, colorectal and cervix cancer screening, SARS-CoV-2 screening test and communication, diabetes, high blood pressure and hypercholesterolemia screening. Regarding the programs for avoiding/stopping drug use: methadone supply, syringe exchange and smoking cessation. Another important service is immunization. Spanish community pharmacists are not legally allowed to vaccinate; however, they contribute through education, or vaccines supply, among others. - For the pillar 7, commu...
Amador-Fernández, N, Jenkinson, SP & Berger, J 2023, 'Vision and practice of self-care for community pharmacy in Switzerland', Exploratory Research in Clinical and Social Pharmacy, vol. 9, pp. 100253-100253.
View/Download from: Publisher's site
View description>>
Switzerland is a federal country with a liberal health system built on private mandatory health insurance where the government has three different roles (health protector, guarantor of the offered care and regulator). Health is mostly considered as a responsibility that lies with the individual person. Swiss health policies do not include the term 'self-care', although, the federal policy strategy established for this decade (Health2030) includes objectives and lines of action, some of which could be classified as self-care. Swiss policies do not specify the role of health professionals; therefore, it is up to each canton (the terminology used to describe a state of the Swiss Confederation), organization or enterprise to stipulate it. Regarding pharmacists, 1844 community pharmacies (CPs) take care of nearly 260,000 patients each day. The CPs play an important role in self-care that includes activities such as improving patients' health literacy, screening for different health problems, self-medication education or recommendation related to non-prescription medication. The government understands and emphasizes the importance of CPs' role in primary health care to overcome some of the health care system challenges, part of these actions related to self-care. However, there is scope for expansion regarding the role of the CPs in self-care. Nowadays the services and activities related are driven by health authorities (i.e., pharmacists' autonomous prescribing, vaccination, strategy for the prevention of non-communicable diseases or digitization of electronic patients' record), professional pharmacy associations (i.e., netCare® or screening tests), health foundations (i.e., prevention of addiction) and/or private stakeholders such as chain pharmacies (i.e., screening tests). The possibility of including some of these services related to self-care (even when no medication is supplied) as covered services for the mandatory health insurance is currently politi...
Anitha, K, Dua, K, Chellappan, DK, Gupta, G, Singh, SK, Lakshmi, SM & Bhatt, S 2023, 'HGF/c-MET: A Potential Target for the Treatment of Various Cancers', Current Enzyme Inhibition, vol. 19, no. 2, pp. 71-80.
View/Download from: Publisher's site
View description>>
Background:Cancer is the abnormal growth of cells in the body due to an imbalance in thenormal apoptotic pathways. The abnormality in the cancer cells makes them malignant. Various types oftreatment, including chemotherapy, radiation therapy, targeted therapy, and immunotherapy (IMT), are usedfor cancer. Mesenchymal-epithelial transition factor (c-Met) belongs to the tyrosine kinase receptor familyand is overexpressed in various types of cancers. c-Met is a proto-oncogene and facilitates a wide range ofbiological functions, including cell proliferation, growth, migration, invasion, and angiogenesis, through interactionwith its sole ligand hepatocyte growth factor (HGF). Currently, various c-mesenchymal-epithelialtransition (c-MET) inhibitors and antibodies are in human trials for their anti-cancer activity.Introduction:The c-MET is a kinase receptor for hepatocyte growth factor (HGF). It is wellrecognizedfor its tumorigenic potential. HGF binding with c-Met leads to c-Met dimerization and c-Met phosphorylation, which in turn activates many intracellular signalling pathways, includingERK1/2, MAPK, STAT3, Rac1, and PI3K/AKT. These pathways regulate the proliferation, invasion,and migration of cancer cells. Upon binding of HGF to c-MET, a series of phosphorylation reactionsget started, which leads to transcription and translation of various proteins, followed by abnormalgrowth of cancerous tissues due to dysregulation of the cell cycle. The HGF/c-MET signalling pathwayshave shown their potential in the development of many cancers, including gastric cancer (GC).Several clinical trials have evaluated the therapeutic benefits of MET-targeted therapies involving variousagents, such as anti-MET antibodies, anti-HGF antibodies, and tyrosine kinase inhibitors (TKIs).Various c-MET inhibitors are in clinical trials. The current review is ...
Ashique, S, Afzal, O, Hussain, A, Zeyaullah, M, Altamimi, MA, Mishra, N, Ahmad, MF, Dua, K, Altamimi, ASA & Anand, K 2023, 'It's all about plant derived natural phytoconstituents and phytonanomedicine to control skin cancer', Journal of Drug Delivery Science and Technology, vol. 84, pp. 104495-104495.
View/Download from: Publisher's site
View description>>
Nanotechnology is an emerging science for controlling cutaneous cancer and related consequences like skin melanoma. Phyto nanomedicine facilitated drug targeting, penetration, and retention with mitigated side effects as a result of topical application. Data and information were collected from various kinds of literature. Data were critically evaluated and analyzed. Due to the immense structural diversity found in them, natural resources continue to be a valuable source of new and innovative chemical entities with potential therapeutic value. Skin cancer (SC) is a deadly disease and a global challenge for healthcare professionals. Considering the frequent emergence of drug resistance, new drug discovery and clinical success are expensive and long-term processes. Therefore, phytochemicals emerged as a new window for therapeutic alternatives with convincing outcomes. These phytoconstituents and phytonanomedicines demonstrated to control SC through diverse mechanistic signaling pathways either by up-regulation or down-regulation. These have been explored in several in vitro and in vivo models. In this review, we addressed causes, pathology, and treatment options using phytonanomedicine or phytoconstituents to control SC followed by mechanistic perspectives. Perspectives on the most important phytochemicals and nanomedicines and their therapeutic potential are included in the current review.
Ashique, S, Gupta, K, Gupta, G, Mishra, N, Singh, SK, Wadhwa, S, Gulati, M, Dureja, H, Zacconi, F, Oliver, BG, Paudel, KR, Hansbro, PM, Chellappan, DK & Dua, K 2023, 'Vitamin D—A prominent immunomodulator to prevent COVID‐19 infection', International Journal of Rheumatic Diseases, vol. 26, no. 1, pp. 13-30.
View/Download from: Publisher's site
View description>>
AbstractCOVID‐19 remains a life‐threatening infectious disease worldwide. Several bio‐active agents have been tested and evaluated in an effort to contain this disease. Unfortunately, none of the therapies have been successful, owing to their safety concerns and the presence of various adverse effects. Various countries have developed vaccines as a preventive measure; however, they have not been widely accepted as effective strategies. The virus has proven to be exceedingly contagious and lethal, so finding an effective treatment strategy has been a top priority in medical research. The significance of vitamin D in influencing many components of the innate and adaptive immune systems is examined in this study. This review aims to summarize the research on the use of vitamin D for COVID‐19 treatment and prevention. Vitamin D supplementation has now become an efficient option to boost the immune response for all ages in preventing the spread of infection. Vitamin D is an immunomodulator that treats infected lung tissue by improving innate and adaptive immune responses and downregulating the inflammatory cascades. The preventive action exerted by vitamin D supplementation (at a specific dose) has been accepted by several observational research investigations and clinical trials on the avoidance of viral and acute respiratory dysfunctions. To assess the existing consensus about vitamin D supplementation as a strategy to treat and prevent the development and progression of COVID‐19 disease, this review intends to synthesize the evidence around vitamin D in relation to COVID‐19 infection.
Awasthi, R, Singh, AK, Mishra, G, Maurya, A, Dhiman, N, Kharkwal, H, Sharma, B, Jha, NK, Dureja, H, Dua, K, de Jesus Andreoli Pinto, T & Kulkarni, GT 2023, 'Diagnosis and Clinical Aspects of Lung Cancer: A Special Emphasis onDrug Targeting to Cancer Cells through Nanoparticles', Letters in Drug Design & Discovery, vol. 20, no. 5, pp. 499-516.
View/Download from: Publisher's site
View description>>
Abstract:Lung cancer is a leading cause of cancer-related deaths globally. The availability of successfulanticancer agents in the market is limited, and the development process of a new drug molecule is slowand difficult. The currently available commercial formulations are not sufficient to produce the desiredtherapeutic response within a specific time limit. Therefore, there is an urgent need to develop novelnanocarrier-based therapies to defeat the restrictions of existing therapeutics. Nanoparticles have beeninvestigated as novel formulations but are often inefficient in practical applications. However, severalunanswered questions and challenges exist in their clinical development; thus, a better understanding oftheir influence on cancer biology, stability, and toxicity needs to be gained. This review discusses differenttypes of lung cancers as well as diagnostic approaches to lung cancer. The review also explores thedrug targeting mechanisms to cancer cells through nanoparticles and multi-drug resistance-associatedchallenges in lung cancer therapy. Various nanocarrier systems that are safe and effective for drug deliveryin the treatment of lung cancer have been discussed. This communication will be of high relevance tothe biological, formulation, and translational scientists working in the field of cancer biology and drugdelivery.
Bani Saeid, A, Patel, VK, Mehndiratta, S, Rajput, R, Kundu, RK, Singh, SK, Chellappan, DK, Kokkinis, S, De Rubis, G, Collet, T, Paudel, KR, Hansbro, PM & Dua, K 2023, 'Dissecting the in vitro fate of plant-derived bioactive encapsulated nanoparticles in lung diseases', Food Bioscience, vol. 56, pp. 103205-103205.
View/Download from: Publisher's site
Bhat, AA, Afzal, O, Agrawal, N, Thapa, R, Almalki, WH, Kazmi, I, Alzarea, SI, Altamimi, ASA, Kukreti, N, Chakraborty, A, Singh, SK, Dua, K & Gupta, G 2023, 'A comprehensive review on the emerging role of long non-coding RNAs in the regulation of NF-κB signaling in inflammatory lung diseases', International Journal of Biological Macromolecules, vol. 253, pp. 126951-126951.
View/Download from: Publisher's site
Bhat, AA, Gilhotra, R, Singh, Y, Sharma, S, Jesus Andreoli Pinto, TD, Ferraz, HG, Singh, SK, Dua, K & Gupta, G 2023, 'Advanced Drug-Delivery Approaches in Managing P53-Mediated Lung Diseases Remodeling', Nanomedicine, vol. 18, no. 7, pp. 583-587.
View/Download from: Publisher's site
Bhat, AA, Gupta, G, Afzal, O, Kazmi, I, Al-Abbasi, FA, Alfawaz Altamimi, AS, Almalki, WH, Alzarea, SI, Singh, SK & Dua, K 2023, 'Neuropharmacological effect of risperidone: From chemistry to medicine', Chemico-Biological Interactions, vol. 369, pp. 110296-110296.
View/Download from: Publisher's site
Bhat, AA, Thapa, R, Afzal, O, Agrawal, N, Almalki, WH, Kazmi, I, Alzarea, SI, Altamimi, ASA, Prasher, P, Singh, SK, Dua, K & Gupta, G 2023, 'The pyroptotic role of Caspase-3/GSDME signalling pathway among various cancer: A Review', International Journal of Biological Macromolecules, vol. 242, pp. 124832-124832.
View/Download from: Publisher's site
Bhat, AA, Thapa, R, Goyal, A, Subramaniyan, V, Kumar, D, Gupta, S, Singh, SK, Dua, K & Gupta, G 2023, 'Curcumin-based Nanoformulations As an Emerging Therapeutic Strategy for Inflammatory Lung Diseases', Future Medicinal Chemistry, vol. 15, no. 7, pp. 583-586.
View/Download from: Publisher's site
Bhatt, S, Devadoss, T, Jha, NK, Baidya, M, Gupta, G, Chellappan, DK, Singh, SK & Dua, K 2023, 'Targeting inflammation: a potential approach for the treatment of depression', Metabolic Brain Disease, vol. 38, no. 1, pp. 45-59.
View/Download from: Publisher's site
View description>>
Major depressive disorder (MDD) or Depression is one of the serious neuropsychiatric disorders affecting over 280 million people worldwide. It is 4th important cause of disability, poor quality of life, and economic burden. Women are more affected with the depression as compared to men and severe depression can lead to suicide. Most of the antidepressants predominantly work through the modulation on the availability of monoaminergic neurotransmitter (NTs) levels in the synapse. Current antidepressants have limited efficacy and tolerability. Moreover, treatment resistant depression (TRD) is one of the main causes for failure of standard marketed antidepressants. Recently, inflammation has also emerged as a crucial factor in pathological progression of depression. Proinflammatory cytokine levels are increased in depressive patients. Antidepressant treatment may attenuate depression via modulation of pathways of inflammation, transformation in structure of brain, and synaptic plasticity. Hence, targeting inflammation may be emerged as an effective approach for the treatment of depression. The present review article will focus on the preclinical and clinical studies that targets inflammation. In addition, it also concentrates on the therapeutic approaches' that targets depression via influence on the inflammatory signaling pathways. Graphical abstract demonstrate the role of various factors in the progression and neuroinflammation, oxidative stress. It also exhibits the association of neuroinflammation, oxidative stress with depression.
Bhatt, S, Kanoujia, J, Mohana Lakshmi, S, Patil, CR, Gupta, G, Chellappan, DK & Dua, K 2023, 'Role of Brain-Gut-Microbiota Axis in Depression: Emerging TherapeuticAvenues', CNS & Neurological Disorders - Drug Targets, vol. 22, no. 2, pp. 276-288.
View/Download from: Publisher's site
View description>>
Abstract:The human gut microbiota plays a significant role in the pathophysiology of central nervoussystem-related diseases. Recent studies suggest correlations between the altered gut microbiota andmajor depressive disorder (MDD). It is proposed that normalization of the gut microbiota alleviatesMDD. The imbalance of brain-gut-microbiota axis also results in dysregulation of the hypothalamicpituitary-adrenal (HPA) axis. This imbalance has a crucial role in the pathogenesis of depression.Treatment strategies with certain antibiotics lead to the depletion of useful microbes and thereby inducedepression like effects in subjects. Microbiota is also involved in the synthesis of various neurotransmitters(NTs) like 5-hydroxy tryptamine (5-HT; serotonin), norepinephrine (NE) and dopamine(DA). In addition to NTs, the gut microbiota also has an influence on brain derived neurotrophic factor(BDNF) levels. Recent research findings have exhibited that transfer of stress prone microbiota inmice is also responsible for depression and anxiety-like behaviour in animals. The use of probiotics,prebiotics, synbiotics and proper diet have shown beneficial effects in the regulation of depressionpathogenesis. Moreover, transplantation of fecal microbiota from depressed individuals to normal subjectsalso induces depression-like symptoms. With the precedence of limited therapeutic benefits frommonoamine targeting drugs, the regulation of brain-gut microbiota is emerging as a new treatmentmodality for MDDs. In this review, we elaborate on the significance of brain-gut-microbiota axis inthe progression of MDD, particularly focusing on the modulation of the gut microbiota as a mode oftreating MDD.
Bhatt, S, Upadhyay, T, Patil, CR, Pai, KSR, Chellappan, DK & Dua, K 2023, 'Role of Oxidative Stress in Pathophysiological Progression ofSchizophrenia', Current Psychiatry Research and Reviews, vol. 19, no. 1, pp. 11-27.
View/Download from: Publisher's site
View description>>
Background:Oxidative stress (OS) is a chief contributing factor to the pathologicaladvancement of Schizophrenia (SCZ). In recent years, OS has emerged as an important aspectin SCZ research and provides abundant opportunities and expectations for a better understandingof its pathophysiology, which may lead to novel treatment strategies.Introduction:The increased OS and formation of reactive oxygen species (ROS) leads to damageto cellular macromolecules. The excessive OS is associated with several physiological processes,such as dysfunction of mitochondria and neuroglia, inflammation, underactive Nmethyl-D-aspartate (NMDA) receptors, and the abnormalities of fast-spiking gammaaminobutyricacid (GABA) interneurons.Methods:The methods adopted for the study are mainly based on the secondary search througha systemic literature review. The role of various anti-oxidants, including vitamins, is discussedin the reduction of SCZ.Results:Various preclinical and clinical studies suggest the involvement of OS and ROS in theprogression of the disease. Recent human trials have shown the treatment with antioxidants tobe effective in ameliorating symptoms and delaying the progression of SCZ pathology. Thestudies have demonstrated that innate and dietary antioxidants exert beneficial effects by reducingthe severity of positive symptoms (PS) and/or negative symptoms (NS) of SCZ.Conclusion:The present review critically evaluates the effect of antioxidants and highlightsthe role of OS in SCZ.
Chakraborty, A, Paudel, KR, Wang, C, De Rubis, G, Chellappan, DK, Hansbro, PM, Samuel, CS & Dua, K 2023, 'Anti-inflammatory and anti-fibrotic effects of berberine-loaded liquid crystalline nanoparticles.', EXCLI J, vol. 22, pp. 1104-1108.
View/Download from: Publisher's site
Chan, Y, Raju Allam, VSR, Paudel, KR, Singh, SK, Gulati, M, Dhanasekaran, M, Gupta, PK, Jha, NK, Devkota, HP, Gupta, G, Hansbro, PM, Oliver, BGG, Chellappan, DK & Dua, K 2023, 'Nutraceuticals: unlocking newer paradigms in the mitigation of inflammatory lung diseases', Critical Reviews in Food Science and Nutrition, vol. 63, no. 19, pp. 3302-3332.
View/Download from: Publisher's site
Chatterjee, S, Corrie, L, Hanmantrao, M, Vishwas, S, Kumar, R, Alotaibi, F, Ansari, MJ, Rehman, ZU, Porwal, O, Khursheed, R, Harish, V, Gupta, G, Kumar, B, Singh, PK, Gowthamarajan, K, De, A, Sudhakar, S, Umashankar, MS, Gulati, M, Dua, K & Singh, SK 2023, 'Quality by design-oriented formulation optimization and characterization of guar gum-pectin based oral colon targeted liquisolid formulation of xanthohumol', Journal of Drug Delivery Science and Technology, vol. 82, pp. 104350-104350.
View/Download from: Publisher's site
Corrie, L, Gulati, M, Kaur, J, Awasthi, A, Vishwas, S, Ramanunny, AK, Khursheed, R, Dua, K, Chellappan, DK & Singh, SK 2023, 'Quality by Design-based RP-HPLC Method for Estimation of Curcumin inRat Plasma and Fecal Microbiota Extract-based Solid Self-nano EmulsifyingDrug Delivery System', Current Drug Research Reviews, vol. 15, no. 3, pp. 272-285.
View/Download from: Publisher's site
View description>>
Background:Curcumin (CRM) is known to possess various therapeutic properties,such as anti-inflammatory and antidiabetic properties, and is, therefore, considered to be an effectivetherapeutic.Objective:A sensitive method for the estimation of CRM in plasma, as well as fecal matter-basedsolid self-nano emulsifying drug delivery system (S-SNEDDS), has been reported for the firsttime.Methods:A bioanalytical method was optimized using Box-Behnken Design having 13 runs and 3responses. The optimized method was developed using methanol and water (70:30 v/v) with a flowrate of 1 mL/min. Quercetin was used as an internal standard. A specificity test was also performedfor the developed CRM solid self-nano emulsifying drug delivery system.Results:The retention time of CRM was found to be 14.18 minutes. The developed method wasvalidated and found to be linear in the range of 50-250 ng/mL with an R2 of 0.999. Accuracy studiesindicated that CRM had a percentage recovery of less than 105% and more than 95%, respectively.Precision studies were carried out for inter, intraday, and inter-analyst precision, and the%RSD was found to be less than 2%. The limit of detection (LOD) and limit of quantification(LOQ) were found to be 3.37 ng/mL and 10.23 ng/mL, respectively. Stability studies for shortterm,long term and freeze-thaw cycles showed a %RSD of less than 2%, indicating the stability ofCRM in the plasma matrix. Moreover, the blank fecal microbiota extract slurry did not show anypeak at the retention time of CRM in a CRM-loaded solid nanoemulsifying drug delivery systemcontaining fecal microbiota extract indicating its specificity.Conclusion:Hence,...
Dahiya, M, Awasthi, R, Dua, K & Dureja, H 2023, 'Sorafenib tosylate loaded superparamagnetic nanoparticles: Development, optimization and cytotoxicity analysis on HepG2 human hepatocellular carcinoma cell line', Journal of Drug Delivery Science and Technology, vol. 79, pp. 104044-104044.
View/Download from: Publisher's site
Dahiya, M, Awasthi, R, Yadav, JP, Sharma, S, Dua, K & Dureja, H 2023, 'Chitosan based sorafenib tosylate loaded magnetic nanoparticles: Formulation and in-vitro characterization', International Journal of Biological Macromolecules, vol. 242, pp. 124919-124919.
View/Download from: Publisher's site
Datsyuk, JK, Paudel, KR, Rajput, R, Kokkinis, S, El Sherkawi, T, Singh, SK, Gupta, G, Chellappan, DK, Yeung, S, Hansbro, PM, Oliver, BGG, Santos, HA, Dua, K & De Rubis, G 2023, 'Emerging applications and prospects of NFκB decoy oligodeoxynucleotides in managing respiratory diseases', Chemico-Biological Interactions, vol. 385, pp. 110737-110737.
View/Download from: Publisher's site
De Rubis, G, Paudel, KR, Liu, G, Agarwal, V, MacLoughlin, R, de Jesus Andreoli Pinto, T, Singh, SK, Adams, J, Nammi, S, Chellappan, DK, Oliver, BGG, Hansbro, PM & Dua, K 2023, 'Berberine-loaded engineered nanoparticles attenuate TGF-β-induced remodelling in human bronchial epithelial cells', Toxicology in Vitro, vol. 92, pp. 105660-105660.
View/Download from: Publisher's site
Dewanjee, S, Chakraborty, P, Bhattacharya, H, Singh, SK, Dua, K, Dey, A & Jha, NK 2023, 'Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy', Drug Discovery Today, vol. 28, no. 1, pp. 103409-103409.
View/Download from: Publisher's site
View description>>
Flavonoids are an interesting class of biomolecules that exhibit cancer-inhibitory effects through both chemopreventive and chemotherapeutic activities. However, poor pharmacokinetics (PK) and biopharmaceutical attributes affect their therapeutic efficacy. One of the most promising approaches to resolve these issues is to formulate flavonoids in nanosystems. Different flavonoid nanoformulations have shown therapeutic superiority over free flavonoids. Functionalization of nanoparticles (NPs) further improves their therapeutic efficacy by facilitating site-specific delivery and reducing nonspecific toxicities. In this review, we highlight recent developments in the field of flavonoid-based NPs to gain translational insights into the potential applications of flavonoid-based nanocarriers in cancer management.
Duarte, J, Sharma, A, Sharifi, E, Damiri, F, Berrada, M, Khan, MA, Singh, SK, Dua, K, Veiga, F, Mascarenhas-Melo, F, Pires, PC & Paiva-Santos, AC 2023, 'Topical delivery of nanoemulsions for skin cancer treatment', Applied Materials Today, vol. 35, pp. 102001-102001.
View/Download from: Publisher's site
Fatima, R, Prasher, P, Sharma, M, Chellappan, DK, Gupta, G, Singh, SK, Patravale, VB & Dua, K 2023, 'Aminated Polysaccharides: Unveiling a new frontier for enhanced therapeutic efficacy', Journal of Drug Delivery Science and Technology, vol. 89, pp. 105090-105090.
View/Download from: Publisher's site
Fatima, R, Sharma, M, Prasher, P, Singh, SK, Chellappan, DK, Kaur, IP & Dua, K 2023, 'Diversity of Rationally Modified Polysaccharides for Pharmaceutical Applications', ChemistrySelect, vol. 8, no. 20.
View/Download from: Publisher's site
View description>>
AbstractThe pressing need for the development of diversified and non‐toxic biomaterials in recent decades has led to the emergence of novel and valuable structural modifications in polysaccharides to broaden their spectrum of applications. Polysaccharides are macromolecules with multifaceted diverse structures and exhibit wide range of pharmacological and biological activities. Naturally occurring polysaccharides such as starch, chitosan, alginate, acetalated dextran and pectin could potentially negate major concerns associated with the selection of suitable polysaccharides without compromising their unique bioactive nature. Chemical modification of polysaccharides offers distinctive benefits such as improved biocompatibility, stability, solubility, and functionality making them more valuable for a variety of biomedical applications such as drug delivery, gene delivery, cell culture technology and tissue engineering. The present review is a compendium of relevant chemically modified polysaccharides and discusses their role in diverse fields of pharmacy and medicine.
Goyal, AK, Dua, K, Jain, SK & Jain, S 2023, 'Foreword', Therapeutic Nanocarriers in Cancer Treatment: Challenges and Future Perspective, p. i.
Gulati, N, Dua, K & Dureja, H 2023, 'Enhancing the Therapeutic Potential of Nanomedicines by Modifying SurfaceCharacteristics', Current Drug Delivery, vol. 20, no. 8, pp. 1031-1036.
View/Download from: Publisher's site
View description>>
Abstract:Nanomedicines have been used over time because of their significant impact on human healthcare for the prevention, early detection, diagnosis, treatment, and follow-up of a wide range of illnesses.Nanomedicines must be adequately characterized in order to develop well-defined nanomedicines withtherapeutic value. The surface charge of nanomedicines plays an important role to determine how theyinteract with biological components where the zeta potential is a useful tool for describing the chemicalcomposition of particle surfaces, such as functional groups, adsorption/desorption, and so on. The maingoal of this review is to present an overview of the impact of nanomedicines' surface charges on absorption,distribution, metabolism, and in vivo drug release, for example negatively charged nanoparticlesdiffuse well through mucus for mucosal drug delivery, whereas positively charged nanoparticles arepreferred for transvascular transport, tumor penetration, and cellular absorption. In this review, we alsohighlight how to improve nanomedicines' therapeutic potential by altering their surface characteristicswith the help of various polymers. Future research should be focused on enhancing the therapeutic efficiencyof nanomedicines by changing their surface properties, as well as conducting in-depth mechanisticstudies by changing the surface properties of nanomedicines for the efficient treatment of diseaseswith low or no nanomedicine toxicity.
Gupta, G, Bhat, AA, Goyal, A, Singla, N, Gupta, S, Sharma, S, Bhatt, S & Dua, K 2023, 'Exploring ACSL4/LPCAT3/ALOX15 and SLC7A11/GPX4/NFE2L2 as Potential Targets in Ferroptosis-Based Cancer Therapy', Future Medicinal Chemistry, vol. 15, no. 14, pp. 1209-1212.
View/Download from: Publisher's site
Gupta, G, Hussain, MS, Thapa, R, Dahiya, R, Mahapatra, DK, Bhat, AA, Singla, N, Subramaniyan, V, Rawat, S, Jakhmola, V, S, R & Dua, K 2023, 'Hope on the Horizon: Wharton’s Jelly Mesenchymal Stem Cells in the Fight Against COVID-19', Regenerative Medicine, vol. 18, no. 9, pp. 675-678.
View/Download from: Publisher's site
Gupta, G, Oliver, BG, Dua, K, Ali, MK & Dave, P 2023, 'Preface', Targeting Epigenetics in Inflammatory Lung Diseases, pp. v-vi.
Gupta, S, Grewal, AS, Deswal, G, Singh, S, Vishwas, S, Badavath, V, Dua, K, Thakur, P & Singh, TG 2023, 'In silico docking studies of Yucca gloriosa L. phytoconstituents with TNF-α, IL-6 and IL-13 receptor against Asthma', Chemical Biology Letters, vol. 10, no. 1.
View description>>
Yucca gloriosa L has been comprehensively assessed in vitro and in vivo for its action against asthma Y gloriosa L is a rich source of phenolic compounds such as gloriosaols A E and yuccaols A E which exhibit potent antioxidant activity Gloriosaols A E and yuccaols A E are structurally related to corticosteroids The current study describes the in silico docking of some important anti asthmatic phytoconstituents from the plant Y gloriosa L with molecular targets of asthma Toward the recognition of the binding methods of these pharmacologically dynamic components molecular modelling studies were carried out with target proteins i e interleukin IL 6 1N26 IL 13 3LB6 and TNF 2AZ5 using in silico molecular docking The components demonstrated encouraging binding interactions with the amino acid residues at the active sites of these proteins authenticating their verified efficiency as anti asthmatic agents The current research in addition provides insight into the possible herbal drug receptor interaction and synthetic drug montelukast sodium receptor interaction for the possible management of asthma ScienceIn Publishing ISSN 2347 9825
Gupta, S, Grewal, AS, Deswal, G, Singh, S, Vishwas, S, Badavath, V, Dua, K, Thakur, P & Singh, TG 2023, 'In silico docking studies of Yucca gloriosa L. phytoconstituents with TNF-α, IL-6 and IL-13 receptor against Asthma', Chemical Biology Letters, vol. 10, no. 1.
View description>>
Yucca gloriosa L. has been comprehensively assessed in vitro and in vivo for its action against asthma. Y. gloriosa L. is a rich source of phenolic compounds such as gloriosaols A-E and yuccaols A-E, which exhibit potent antioxidant activity. Gloriosaols A-E and yuccaols A-E are structurally related to corticosteroids. The current study describes the in silico docking of some important anti-asthmatic phytoconstituents from the plant Y. gloriosa L. with molecular targets of asthma. Toward the recognition of the binding methods of these pharmacologically dynamic components, molecular modelling studies were carried out with target proteins, i.e., interleukin (IL)-6 (1N26), IL-13 (3LB6) and TNF-α (2AZ5), using in silico molecular docking. The components demonstrated encouraging binding interactions with the amino acid residues at the active sites of these proteins, authenticating their verified efficiency as anti-asthmatic agents. The current research, in addition, provides insight into the possible herbal drug-receptor interaction and synthetic drug montelukast sodium receptor interaction, for the possible management of asthma.
Harish, V, Mohd, S, Tewari, D, Pandey, NK, Vishwas, S, Babu, MR, Salkini, MA, Rehman, ZU, Alotaibi, JT, Alotaibi, RF, Alrashed, FA, Prasher, P, Sharma, N, Gupta, G, Jakhmola, V, Singh, Y, Pinto, TDJA, Paudel, KR, Mittal, N, Singh, TG, Arora, P, Dua, K & Singh, SK 2023, 'Unravelling the role of solid lipid nanoparticles in drug delivery: Journey from laboratory to clinical trial', Journal of Drug Delivery Science and Technology, vol. 85, pp. 104616-104616.
View/Download from: Publisher's site
Hussain, A, Ashique, S, Zaheen Hassan, M, Afzal, O, Asiri, YI, Kumar, P, Dua, K, Webster, TJ, Altamimi, ASA & Altamimi, MA 2023, 'Pharmaceutical contaminants in aquatic systems, conventional and green strategies, recent updates, challenges and policies, and potential outcomes', Journal of Molecular Liquids, vol. 389, pp. 122905-122905.
View/Download from: Publisher's site
Hussain, MS, Afzal, O, Gupta, G, Altamimi, ASA, Almalki, WH, Alzarea, SI, Kazmi, I, Kukreti, N, Gupta, S, Sulakhiya, K, Singh, SK & Dua, K 2023, 'Probing the links: Long non-coding RNAs and NF-κB signalling in atherosclerosis', Pathology - Research and Practice, vol. 249, pp. 154773-154773.
View/Download from: Publisher's site
Hussain, MS, Gupta, G, Afzal, M, Alqahtani, SM, Samuel, VP, Hassan almalki, W, Kazmi, I, Alzarea, SI, Saleem, S, Dureja, H, Singh, SK, Dua, K & Thangavelu, L 2023, 'Exploring the role of lncrna neat1 knockdown in regulating apoptosis across multiple cancer types: A review', Pathology - Research and Practice, vol. 252, pp. 154908-154908.
View/Download from: Publisher's site
Hussain, MS, Gupta, G, Goyal, A, Thapa, R, almalki, WH, Kazmi, I, Alzarea, SI, Fuloria, S, Meenakshi, DU, Jakhmola, V, Pandey, M, Singh, SK & Dua, K 2023, 'From nature to therapy: Luteolin's potential as an immune system modulator in inflammatory disorders', Journal of Biochemical and Molecular Toxicology, vol. 37, no. 11.
View/Download from: Publisher's site
View description>>
AbstractInflammation is an essential immune response that helps fight infections and heal tissues. However, chronic inflammation has been linked to several diseases, including cancer, autoimmune disorders, cardiovascular diseases, and neurological disorders. This has increased interest in finding natural substances that can modulate the immune system inflammatory signaling pathways to prevent or treat these diseases. Luteolin is a flavonoid found in many fruits, vegetables, and herbs. It has been shown to have anti‐inflammatory effects by altering signaling pathways in immune cells. This review article discusses the current research on luteolin's role as a natural immune system modulator of inflammatory signaling mechanisms, such as its effects on nuclear factor‐kappa B, mitogen‐activated protein kinases, Janus kinase/signal transducer and activator of transcription, and inflammasome signaling processes. The safety profile of luteolin and its potential therapeutic uses in conditions linked to inflammation are also discussed. Overall, the data point to Luteolin's intriguing potential as a natural regulator of immune system inflammatory signaling processes. More research is needed to fully understand its mechanisms of action and possible therapeutic applications.
Kakoty, V, Kalarikkal Chandran, S, Gulati, M, Goh, BH, Dua, K & Kumar Singh, S 2023, 'Senolytics: Opening avenues in drug discovery to find novel therapeutics for Parkinson’s Disease', Drug Discovery Today, vol. 28, no. 6, pp. 103582-103582.
View/Download from: Publisher's site
Kannan, S, Chellappan, DK, Kow, CS, Ramachandram, DS, Pandey, M, Mayuren, J, Dua, K & Candasamy, M 2023, 'Transform diabetes care with precision medicine', Health Science Reports, vol. 6, no. 11.
View/Download from: Publisher's site
View description>>
AbstractBackground and AimsDiabetes is a global concern. This article took a closer look at diabetes and precision medicine.MethodsA literature search of studies related to the use of precision medicine in diabetes care was conducted in various databases (PubMed, Google Scholar, and Scopus).ResultsPrecision medicine encompasses the integration of a wide array of personal data, including clinical, lifestyle, genetic, and various biomarker information. Its goal is to facilitate tailored treatment approaches using contemporary diagnostic and therapeutic techniques that specifically target patients based on their genetic makeup, molecular markers, phenotypic traits, or psychosocial characteristics. This article not only highlights significant advancements but also addresses key challenges, particularly focusing on the technologies that contribute to the realization of personalized and precise diabetes care.ConclusionFor the successful implementation of precision diabetes medicine, collaboration and coordination among multiple stakeholders are crucial.
Kannaujiya, VK, De Rubis, G, Paudel, KR, Manandhar, B, Chellappan, DK, Singh, SK, MacLoughlin, R, Gupta, G, Xenaki, D, Kumar, P, Hansbro, PM, Oliver, BGG, Wich, PR & Dua, K 2023, 'Anticancer activity of NFκB decoy oligonucleotide-loaded nanoparticles against human lung cancer', Journal of Drug Delivery Science and Technology, vol. 82, pp. 104328-104328.
View/Download from: Publisher's site
Kanojia, N, Thapa, K, Verma, N, Rani, L, Sood, P, Kaur, G, Dua, K & Kumar, J 2023, 'Update on Mucoadhesive Approaches to target Drug Delivery in Colorectal Cancer', Journal of Drug Delivery Science and Technology, vol. 87, pp. 104831-104831.
View/Download from: Publisher's site
Kaur Sandhu, S, Raut, J, Kumar, S, Singh, M, Ahmed, B, Singh, J, Rana, V, Rishi, P, Ganesh, N, Dua, K & Pal Kaur, I 2023, 'Nanocurcumin and viable Lactobacillus plantarum based sponge dressing for skin wound healing', International Journal of Pharmaceutics, vol. 643, pp. 123187-123187.
View/Download from: Publisher's site
View description>>
Curcumin loaded solid lipid nanoparticles (CSLNs) and probiotic (Lactobacillus plantarum UBLP-40; L. plantarum) were currently co-incorporated into a wound dressing. The combination with manifold anti-inflammatory, anti-infective, analgesic, and antioxidant properties of both curcumin and L. plantarum will better manage complex healing process. Recent reports indicate that polyphenolics like curcumin improve probiotic effects. Curcumin was nanoencapsulated (CSLNs) to improve its bioprofile and achieve controlled release on the wound bed. Bacteriotherapy (probiotic) is established to promote wound healing via antimicrobial activity, inhibition of pathogenic toxins, immunomodulation, and anti-inflammatory actions. Combination of CSLNs with probiotic enhanced (560%) antimicrobial effects against planktonic cells and biofilms of skin pathogen, Staphylococcus aureus 9144. The sterile dressing was devised with selected polymers, and optimized for polymer concentration, and dressing characteristics using a central composite design. It exhibited a swelling ratio of 412 ± 36%, in vitro degradation time of 3 h, optimal water vapor transmission rate of 1516.81 ± 155.25 g/m2/day, high tensile strength, low-blood clotting index, case II transport, and controlled release of curcumin. XRD indicated strong interaction between employed polymers. FESEM revealed a porous sponge like meshwork embedded with L. plantarum and CSLNs. It degraded and released L. plantarum, which germinated in the wound bed. The sponge was stable under refrigerated conditions for up to six months. No translocation of probiotic from wound to the internal organs confirmed safety. The dressing exhibited faster wound closure and lowered bioburden in the wound area in mice. This was coupled with a decrease in TNF-α, MMP-9, and LPO levels; and an increase in VEGF, TGF-β, and antioxidant enzymes such as catalase and GSH, establishing multiple healing pathways. Results were compared with CSLNs and probi...
Kaur, A, Singh, N, Kaur, H, Kakoty, V, Sharma, DS, Khursheed, R, Babu, MR, Harish, V, Gupta, G, Gulati, M, Kumar, P, Dureja, H, Alharthi, NS, Khan, FR, Rehman, ZU, Hakami, MA, Patel, M, Patel, R, Zandi, M, Vishwas, S, Dua, K & Singh, SK 2023, 'Neurodegenerative diseases and brain delivery of therapeutics: Bridging the gap using dendrimers', Journal of Drug Delivery Science and Technology, vol. 87, pp. 104868-104868.
View/Download from: Publisher's site
Kaur, J, Gulati, M, Pal Kaur, I, Patravale, V, Dua, K & Kumar Singh, S 2023, 'Polymeric micelles as potent islet amyloid inhibitors: Current advances and future perspectives', Drug Discovery Today, vol. 28, no. 5, pp. 103571-103571.
View/Download from: Publisher's site
Kaur, P, Khan, H, Grewal, AK, Dua, K & Singh, TG 2023, 'Therapeutic potential of NOX inhibitors in neuropsychiatric disorders', Psychopharmacology, vol. 240, no. 9, pp. 1825-1840.
View/Download from: Publisher's site
Kazmi, I, Shaikh, MAJ, Afzal, O, Alfawaz Altamimi, AS, Almalki, WH, Alzarea, SI, Al-Abbasi, FA, Pandey, M, Dureja, H, Singh, SK, Dua, K & Gupta, G 2023, 'Chitosan-based nano drug delivery system for lung cancer', Journal of Drug Delivery Science and Technology, vol. 81, pp. 104196-104196.
View/Download from: Publisher's site
Kumar, D, Dua, K & Tiwari, S 2023, 'Localized Delivery of Bioactives using Structured Liposomal Gels', Current Pharmaceutical Design, vol. 29, no. 40, pp. 3206-3220.
View/Download from: Publisher's site
View description>>
Abstract:Liposomes have gained a lot of interest for drug delivery applications, and some of these preparationshave been commercialized. These are formulated with biocompatible components and can be used for deliveringa wide range of payloads differing in aqueous solubility and molecular weight. Liposome-based deliveryapproaches are limited mainly by two factors: (a) poor dispersion stability, and (b) pre-mature leakage ofpayloads. In this review, we have discussed the stabilization of liposomal vesicles by their entrapment in hydrogels.Studies reveal that such hydrogels can maintain the structural integrity of liposomes. Release of liposomesfrom the hydrogel network can be modulated through careful screening of matrix former and degree ofits cross-linking. Accordingly, we have reviewed the approaches of stabilizing liposomal vesicles through entrapmentin hydrogels. Application of liposome-embedded hydrogels has been reviewed in context of localizeddrug delivery. Our discussion is focussed on the delivery of bioactives to the skin. Such an approach appearsalluring from the standpoint of minimizing the undesirable distribution of payload(s) the systemic circulationand off-target sites.
Kumar, D, Sharma, P, Mahajan, A, Dhawan, R & Dua, K 2023, 'Pharmaceutical interest of in-silico approaches', Physical Sciences Reviews, vol. 8, no. 9, pp. 2547-2560.
View/Download from: Publisher's site
View description>>
Abstract The virtual environment within the computer using software performed on the computer is known as in-silico studies. These drugs designing software play a vital task in discovering new drugs in the field of pharmaceuticals. These designing programs and software are employed in gene sequencing, molecular modeling, and in assessing the three-dimensional structure of the molecule, which can further be used in drug designing and development. Drug development and discovery is not only a powerful, extensive, and an interdisciplinary system but also a very complex and time-consuming method. This book chapter mainly focused on different types of in-silico approaches along with their pharmaceutical applications in numerous diseases.
Kumar, D, Singla, RK, Sharma, R, Sharma, P, Kumar, L, Kaur, N, Dhawan, RK, Sharma, S & Dua, K 2023, 'Phytochemistry and Polypharmacological Potential of Colebrookea oppositifoliaSmith', Current Topics in Medicinal Chemistry, vol. 23, no. 5, pp. 334-348.
View/Download from: Publisher's site
View description>>
Background:Colebrookea oppositifolia Smith. is a valuable traditional therapeutic plant belonging to the family Lamiaceae. It is a dense and wool-like shrub that is mostly found in sub-tropical regions of some countries of Asia, such as China and India. It has been widely used for the mitigation of nervous system disorders like epilepsy. The active constituents of the plant have ex-hibited antioxidant, anti-microbial, and antifungal properties, which are considered due to the presence of polyphenols and flavonoids as chief chemical constituents. Flavonoids like quercetin, landenein, chrysin, and 5, 6, 7-trimethoxy flavones cause protein denaturation of the microbial cell wall.Objectives:To comprehend and assemble the fragmented pieces of evidence presented on the tradi-tional uses, botany, phytochemistry, and pharmacology of the plant to reconnoiter its therapeutic perspective and forthcoming research opportunities.Methods:The available information on Colebrookea oppositifolia has been established by electron-ically searching peer-reviewed literature from PubMed, Google Scholar, Springer, Scopus, Web of Science, and Science Direct over the earlier few years.Results:The plant has been greatly used for the preparation of many herbal medicines which are used for treating traumatic injuries, fever, rheumatoid arthritis, headache, and gastric problems. From the aerial parts of the plant, a phenylethanoid glycoside named acteoside has been isolated and evaluated for its therapeutic potential viz. immunomodulatory, neuroprotective, hepatoprotec-tive, analgesic, anti-tumour, antispasmodic, antioxidant, antibacterial, free radical scavenger, and improving sexual function. Acteoside showed neuroprotective activities again...
Kumar, S, Shukla, MK, Sharma, AK, Jayaprakash, GK, Tonk, RK, Chellappan, DK, Singh, SK, Dua, K, Ahmed, F, Bhattacharyya, S & Kumar, D 2023, 'Metal‐based nanomaterials and nanocomposites as promising frontier in cancer chemotherapy', MedComm, vol. 4, no. 2.
View/Download from: Publisher's site
View description>>
AbstractCancer is a disease associated with complex pathology and one of the most prevalent and leading reasons for mortality in the world. Current chemotherapy has challenges with cytotoxicity, selectivity, multidrug resistance, and the formation of stemlike cells. Nanomaterials (NMs) have unique properties that make them useful for various diagnostic and therapeutic purposes in cancer research. NMs can be engineered to target cancer cells for early detection and can deliver drugs directly to cancer cells, reducing side effects and improving treatment efficacy. Several of NMs can also be used for photothermal therapy to destroy cancer cells or enhance immune response to cancer by delivering immune‐stimulating molecules to immune cells or modulating the tumor microenvironment. NMs are being modified to overcome issues, such as toxicity, lack of selectivity, increase drug capacity, and bioavailability, for a wide spectrum of cancer therapies. To improve targeted drug delivery using nano‐carriers, noteworthy research is required. Several metal‐based NMs have been studied with the expectation of finding a cure for cancer treatment. In this review, the current development and the potential of plant and metal‐based NMs with their effects on size and shape have been discussed along with their more effective usage in cancer diagnosis and treatment.
Kumari, V, Vishwas, S, Kumar, R, Kakoty, V, Khursheed, R, Babu, MR, Harish, V, Mittal, N, Singh, PK, Alharthi, NS, Hakami, MA, Aba Alkhayl, FF, Gupta, G, Rubis, GD, Paudel, KR, Singh, M, Zandi, M, Oliver, BG, Dua, K & Singh, SK 2023, 'An overview of biomedical applications for gold nanoparticles against lung cancer', Journal of Drug Delivery Science and Technology, vol. 86, pp. 104729-104729.
View/Download from: Publisher's site
Kumbhar, P, Kaur, J, De Rubis, G, Paudel, KR, Prasher, P, Patel, VK, Corrie, L, Chellappan, DK, Gupta, G, Singh, SK, Patravale, V, Disouza, J & Dua, K 2023, 'Inhalation drug delivery in combating pulmonary infections: Advances and challenges', Journal of Drug Delivery Science and Technology, vol. 89, pp. 105022-105022.
View/Download from: Publisher's site
Kumbhar, P, Kolekar, K, Khot, C, Dabhole, S, Salawi, A, Sabei, FY, Mohite, A, Kole, K, Mhatre, S, Jha, NK, Manjappa, A, Singh, SK, Dua, K, Disouza, J & Patravale, V 2023, 'Co-crystal nanoarchitectonics as an emerging strategy in attenuating cancer: Fundamentals and applications', Journal of Controlled Release, vol. 353, pp. 1150-1170.
View/Download from: Publisher's site
Laird, C, Benson, H & Williams, KA 2023, 'Pharmacist interventions in osteoporosis management: a systematic review', Osteoporosis International, vol. 34, no. 2, pp. 239-254.
View/Download from: Publisher's site
Laird, C, Williams, KA & Benson, H 2023, 'Perceptions and practices of aged care pharmacists regarding osteoporosis management: a qualitative study', International Journal of Clinical Pharmacy, vol. 45, no. 4, pp. 913-921.
View/Download from: Publisher's site
View description>>
Abstract Background Osteoporosis is a common but sub-optimally managed disease among aged care residents. Although pharmacists are one of the key healthcare providers responsible for osteoporosis medication management there is limited research on their involvement. Aim This study explored the perceptions and practices of Australian pharmacists regarding osteoporosis management for aged care residents. Method Semi-structured interviews were conducted with aged care pharmacists. Interviews were recorded, transcribed, and analysed using a constructivist grounded theory approach. Results Twenty-one aged care pharmacists were interviewed. Three main themes were identified: osteoporosis is highly prevalent but given low priority, factors affecting pharmacists’ management of osteoporosis, and optimism for the future role of pharmacists in osteoporosis management. The complexity of aged care residents’ healthcare needs and the silent, insidious nature of osteoporosis contribute to the low priority it is afforded. Barriers identified by pharmacists included their current practice model, limited access to residents’ medical histories and difficulties accessing bone mineral density (BMD) testing. Interdisciplinary collaboration and education regarding osteoporosis management were seen as facilitators. Pharmacists were optimistic that an embedded practice model would improve their capacity to influence osteoporosis management. Conclusion
Lirio, ACM, Diaz, VAF, Chellappan, DK, Dua, K, Lourenço, FR & de Jesus Andreoli Pinto, T 2023, 'Development of a Statistical Approach for Microbial Monitoring in Non-sterile Pharmaceutical Environments', Journal of Pharmaceutical Innovation, vol. 18, no. 3, pp. 1362-1370.
View/Download from: Publisher's site
Liu, X, Ali, MK, Zhao, L, Dua, K & Mao, Y 2023, 'The emerging diagnostic and therapeutic roles of small nucleolar RNAs in lung diseases', Biomedicine & Pharmacotherapy, vol. 161, pp. 114519-114519.
View/Download from: Publisher's site
Low, LE, Kong, CK, Yap, W-H, Siva, SP, Gan, SH, Siew, WS, Ming, LC, Lai-Foenander, AS, Chang, SK, Lee, W-L, Wu, Y, Khaw, K-Y, Ong, YS, Tey, BT, Singh, SK, Dua, K, Chellappan, DK & Goh, B-H 2023, 'Hydroxychloroquine: Key therapeutic advances and emerging nanotechnological landscape for cancer mitigation', Chemico-Biological Interactions, vol. 386, pp. 110750-110750.
View/Download from: Publisher's site
View description>>
Hydroxychloroquine (HCQ) is a unique class of medications that has been widely utilized for the treatment of cancer. HCQ plays a dichotomous role by inhibiting autophagy induced by the tumor microenvironment (TME). Preclinical studies support the use of HCQ for anti-cancer therapy, especially in combination with conventional anti-cancer treatments since they sensitize tumor cells to drugs, potentiating the therapeutic activity. However, clinical evidence has suggested poor outcomes for HCQ due to various obstacles, including non-specific distribution, low aqueous solubility and low bioavailability at target sites, transport across tissue barriers, and retinal toxicity. These issues are addressable via the integration of HCQ with nanotechnology to produce HCQ-conjugated nanomedicines. This review aims to discuss the pharmacodynamic, pharmacokinetic and antitumor properties of HCQ. Furthermore, the antitumor performance of the nanoformulated HCQ is also reviewed thoroughly, aiming to serve as a guide for the HCQ-based enhanced treatment of cancers. The nanoencapsulation or nanoconjugation of HCQ with nanoassemblies appears to be a promising method for reducing the toxicity and improving the antitumor efficacy of HCQ.
Machado, FLDS, Cañás, M, Doubova, SV, Urtasun, MA, Marín, GH, Osorio-de-Castro, CGS, Albuquerque, FC, Ribeiro, TB, Pont, L, Crisóstomo Landeros, J, Roldán Saelzer, J, Sepúlveda Viveros, D, Acosta, A, Machado Beltrán, MA, Gordillo Alas, LI, Orellana Tablas, LA, Benko, R, Convertino, I, Bonaso, M, Tuccori, M, Kirchmayer, U, Contreras Sánchez, SE, Rodríguez-Tanta, LY, Gutierrez Aures, Y, Lin, B, Alipour-Haris, G, Eworuke, E & Lopes, LC 2023, 'Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison', Regulatory Toxicology and Pharmacology, vol. 144, pp. 105485-105485.
View/Download from: Publisher's site
Mahant, S, Sharma, AK, Gandhi, H, Wadhwa, R, Dua, K & Kapoor, DN 2023, 'Emerging Trends and Potential Prospects in Vaginal Drug Delivery', Current Drug Delivery, vol. 20, no. 6, pp. 730-751.
View/Download from: Publisher's site
View description>>
Abstract:The vagina is an essential part of the female reproductive system and offers many potentialbenefits over conventional drug delivery, including a large surface area for drug absorption, relativelylow enzymatic activity, avoiding first-pass effects, and ease of administration. The vaginalmucosal cavity is an effective route for administering therapeutic agents that are intended both forlocal and systemic administration. The present review provides a comprehensive overview of recenttrends and developments in vaginal drug delivery. Marketed formulations and products under clinicalstudy are also reviewed. Various novel vaginal delivery systems have been studied in recentyears as effective tools for delivering a range of therapeutic agents to the vagina. These systems offernumerous benefits, including sustained delivery, improved bioavailability, effective permeation,and higher efficacy. The recent focus of the scientific community is on the development of safe andefficient drug delivery systems, such as nanoparticles, microparticles, vesicular systems, vaginalrings, microneedles, etc., for vaginal application. Various factors, such as the physicochemical propertiesof the drugs, the volume and composition of the vaginal fluid, the pH of the vaginal fluid, thethickness of the vaginal epithelium, and the influence of sexual intercourse may influence the releaseof drugs from the delivery system and subsequent absorption from the vaginal route. To date,only a limited number of in vivo studies on novel vaginal DDS have been reported. Additionally,drug release kinetics under varying vaginal environments is also not well understood. More researchis needed to ensure the suitability, biocompatibility, and therapeutic effectiveness of novel DDS forvaginal delivery. Although numerous strategies and interventions have been developed, clinicaltranslation of these systems remains a challenge. The toxi...
Mahanur, VB, Rajge, RR, Pal, RS, Chaitanya, MVNL, Vishwas, S, Gupta, S, Gupta, G, Kumar, D, Oguntibeju, OO, ur Rehman, Z, Aba Alkhayl, FF, Thakur, V, Pandey, P, Mazumder, A, Adams, J, Dua, K & Singh, SK 2023, 'Harnessing unexplored medicinal values of the red listed South African weed Erigeron bonariensis: From ethnobotany to biomedicine', South African Journal of Botany, vol. 160, pp. 535-546.
View/Download from: Publisher's site
Malik, R, Paudel, KR, Manandhar, B, De Rubis, G, Shen, J, Mujwar, S, Singh, TG, Singh, SK, Gupta, G, Adams, J, MacLoughlin, R, Oliver, BGG, Hansbro, PM, Chellappan, DK & Dua, K 2023, 'Agarwood oil nanoemulsion counteracts LPS-induced inflammation and oxidative stress in RAW264.7 mouse macrophages', Pathology - Research and Practice, vol. 251, pp. 154895-154895.
View/Download from: Publisher's site
Malyla, V, De Rubis, G, Paudel, KR, Chellappan, DK, Hansbro, NG, Hansbro, PM & Dua, K 2023, 'Berberine nanostructures attenuate ß-catenin, a key component of epithelial mesenchymal transition in lung adenocarcinoma', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 396, no. 12, pp. 3595-3603.
View/Download from: Publisher's site
View description>>
AbstractLung cancer (LC) is the leading cause of cancer-related deaths globally. It accounts for more than 1.9 million cases each year due to its complex and poorly understood molecular mechanisms that result in unregulated cell proliferation and metastasis. β-Catenin is a developmentally active protein that controls cell proliferation, metastasis, polarity and cell fate during homeostasis and aids in cancer progression via epithelial–mesenchymal transition. Therefore, inhibition of the β-catenin pathway could attenuate the progression of LC. Berberine, an isoquinoline alkaloid which is known for its anti-cancer and anti-inflammatory properties, demonstrates poor solubility and bioavailability. In our study, we have encapsulated berberine into liquid crystalline nanoparticles to improve its physiochemical functions and studied if these nanoparticles target the β-catenin pathway to inhibit the human lung adenocarcinoma cell line (A549) at both gene and protein levels. We observed for the first time that berberine liquid crystalline nanoparticles at 5 µM significantly attenuate the expression of the β-catenin gene and protein. The interaction between berberine and β-catenin was further validated by molecular simulation studies. Targeting β-catenin with berberine nanoparticles represents a promising strategy for the management of lung cancer progression.
Malyla, V, Paudel, KR, De Rubis, G, Hansbro, NG, Hansbro, PM & Dua, K 2023, 'Cigarette smoking induces lung cancer tumorigenesis via upregulation of the WNT/β-catenin signaling pathway', Life Sciences, vol. 326, pp. 121787-121787.
View/Download from: Publisher's site
Marwaha, MG, Awasthi, R, Marwaha, RK, Prasher, P, Gulati, M, Singh, SK, Anand, K, Gupta, G, Chellappan, DK, Dua, K & Dureja, H 2023, 'Emerging Applications of Polymeric Nanoparticles in Tumor Targeting', Current Nanoscience, vol. 19, no. 5, pp. 677-696.
View/Download from: Publisher's site
View description>>
Abstract:Nanoparticles are well-established carriers for targeted delivery of bioactive polymericnanoparticles (PNPs). They have attracted significant attention from pharmaceutical scientists globallydue to their wide range of applications in the medical field. The encapsulation of drugs into thenanoparticles offers several unique characteristics leading to prolonged circulation, improved druglocalization, and thus enhanced drug efficacy. It also provides a better understanding of the molecularbasis of the disease. Nanoparticles allow efficient maintenance of medication cycles at the targetsite, with less exposure to normal cells and thus decreasing the rehabilitation period. Despite extensivedevelopments in the field of nanotechnology, specifically in drug delivery, only a few nanotechnology-based products are currently available in the market. Thus, further advanced explorationis necessary to make nanoparticles useful for the betterment of mankind. This review is focused onrecent advancements in pharmaceutical nanotechnology with special emphasis on polymers usedfor the preparation of PNPs and their emerging applications in tumor-targeting. This manuscriptalso highlights the recent patents disclosing PNPs for tumor targeting.
Mascarenhas-Melo, F, Mathur, A, Murugappan, S, Sharma, A, Tanwar, K, Dua, K, Singh, SK, Mazzola, PG, Yadav, DN, Rengan, AK, Veiga, F & Paiva-Santos, AC 2023, 'Inorganic nanoparticles in dermopharmaceutical and cosmetic products: Properties, formulation development, toxicity, and regulatory issues', European Journal of Pharmaceutics and Biopharmaceutics, vol. 192, pp. 25-40.
View/Download from: Publisher's site
View description>>
The use of nanotechnology strategies is a current hot topic, and research in this field has been growing significantly in the cosmetics industry. Inorganic nanoparticles stand out in this context for their distinctive physicochemical properties, leading in particular to an increased refractive index and absorption capacity giving them a broad potential for cutaneous applications and making them of special interest in research for dermopharmaceutical and cosmetic purposes. This performance is responsible for its heavy inclusion in the manufacture of skin health products such as sunscreens, lotions, beauty creams, skin ointments, makeup, and others. In particular, their suitable bandgap energy characteristics allow them to be used as photocatalytic semiconductors. They provide excellent UV absorption, commonly known as UV filters, and are responsible for their wide worldwide use in sunscreen formulations without the undesirable white residue after consumer application. In addition, cosmetics based on inorganic nanoparticles have several additional characteristics relevant to formulation development, such as being less expensive compared to other nanomaterials, having greater stability, and ensuring less irritation, itching, and propensity for skin allergies. This review will address in detail the main inorganic nanoparticles used in dermopharmaceutical and cosmetic products, such as titanium dioxide, zinc oxide, silicon dioxide, silver, gold, copper, and aluminum nanoparticles, nanocrystals, and quantum dots, reporting their physicochemical characteristics, but also their additional intrinsic properties that contribute to their use in this type of formulations. Safety issues regarding inorganic nanoparticles, based on toxicity studies, both to humans and the environment, as well as regulatory affairs associated with their use in dermopharmaceuticals and cosmetics, will be addressed.
Mohammadi, B, Dua, K, Saghafi, M, Singh, SK, Heydarifard, Z & Zandi, M 2023, 'COVID‐19‐induced autoimmune thyroiditis: Exploring molecular mechanisms', Journal of Medical Virology, vol. 95, no. 8, p. e29001.
View/Download from: Publisher's site
View description>>
AbstractSevere acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) damages multiple organs, including the thyroid, by direct invasion and cell entry via angiotensin‐converting enzyme 2 or indirectly by promoting excessive inflammation in the body. The immune system is a critical factor in antiviral immunity and disease progression. In the context of SARS‐CoV‐2 infection, the immune system may become overly activated, resulting in a shift from regulatory to effector responses, which may subsequently promote the development and progression of autoimmune diseases. The incidence of autoimmune thyroid diseases, such as subacute thyroiditis, Graves' disease, and Hashimoto's thyroiditis, increases in individuals with COVID‐19 infection. This phenomenon may be attributed to aberrant responses of T‐cell subtypes, the presence of autoantibodies, impaired regulatory cell function, and excessive production of inflammatory cytokines, namely interleukin (IL)‐6, IL‐1β, interferon‐γ, and tumor necrosis factor‐α. Therefore, insights into the immune responses involved in the development of autoimmune thyroid disease according to COVID‐19 can help identify potential therapeutic approaches and guide the development of effective interventions to alleviate patients' symptoms.
Mortlock, R, Smith, V, Nesci, I, Bertoldi, A, Ho, A, El Mekkawi, Z, Kakuzada, L, Williams, K, Pont, L, De Rubis, G & Dua, K 2023, 'A comparative evaluation of propranolol pharmacokinetics in obese versus ideal weight individuals: A blueprint towards a personalised medicine', Chemico-Biological Interactions, vol. 371, pp. 110351-110351.
View/Download from: Publisher's site
Okaiyeto, K, Kerebba, N, Rautenbach, F, Kumar Singh, S, Dua, K & Oguntibeju, OO 2023, 'UPLC-ESI-QTOF-MS phenolic compounds identification and quantification from ethanolic extract of Myrtus communis ‘Variegatha’: In vitro antioxidant and antidiabetic potentials', Arabian Journal of Chemistry, vol. 16, no. 2, pp. 104447-104447.
View/Download from: Publisher's site
Pandey, M, Lang, HX, Loh, JS, Chai, YL, Tee, HL, Mayuren, J, Candasamy, M, Gorain, B, Jain, N, Gupta, G & Dua, K 2023, 'Dendrimer platform against prostate cancer: Recent update on new horizon of treatment', Journal of Drug Delivery Science and Technology, vol. 85, pp. 104589-104589.
View/Download from: Publisher's site
Parveen, SR, Wadhwa, S, Babu, MR, Vishwas, S, Corrie, L, Awasthi, A, Khan, FR, Al-Bazi, MM, Alharthi, NS, Alotaibi, F, Gupta, G, Pandey, NK, Kumar, B, Kumbhar, P, Disouza, J, Gulati, M, Neelamraju, J, Madempudi, RS, Dua, K & Singh, SK 2023, 'Formulation of chrysin loaded nanostructured lipid carriers using Box Behnken design, its characterization and antibacterial evaluation alone and in presence of probiotics co-loaded in gel', Journal of Drug Delivery Science and Technology, vol. 84, pp. 104411-104411.
View/Download from: Publisher's site
Patel, VK, Vishwas, S, Kumar, R, De Rubis, G, Shukla, SD, Paudel, KR, Manandhar, B, Singh, TG, Chellappan, DK, Gulati, M, Kaur, IP, Allam, VSRR, Hansbro, PM, Oliver, BG, MacLoughlin, R, Singh, SK & Dua, K 2023, 'Tackling the cytokine storm using advanced drug delivery in allergic airway disease', Journal of Drug Delivery Science and Technology, vol. 82, pp. 104366-104366.
View/Download from: Publisher's site
Paudel, KR, Rajput, R, De Rubis, G, Raju Allam, VSR, Williams, KA, Singh, SK, Gupta, G, Salunke, P, Hansbro, PM, Gerlach, J & Dua, K 2023, 'In vitro anti-cancer activity of a polyherbal preparation, VEDICINALS®9, against A549 human lung adenocarcinoma cells', Pathology - Research and Practice, vol. 250, pp. 154832-154832.
View/Download from: Publisher's site
Prajapat, VM, Mahajan, S, Paul, PG, Aalhate, M, Mehandole, A, Madan, J, Dua, K, Chellappan, DK, Singh, SK & Singh, PK 2023, 'Nanomedicine: A pragmatic approach for tackling melanoma skin cancer', Journal of Drug Delivery Science and Technology, vol. 83, pp. 104394-104394.
View/Download from: Publisher's site
Prasher, P, Sharma, M, Chan, Y, Singh, SK, Anand, K, Dureja, H, Jha, NK, Gupta, G, Zacconi, F, Chellappan, DK & Dua, K 2023, 'Recent Trends in Rationally Designed Molecules as Kinase Inhibitors', Current Medicinal Chemistry, vol. 30, no. 13, pp. 1529-1567.
View/Download from: Publisher's site
View description>>
:Protein kinases modulate the structure and function of proteins by adding phosphategroups to threonine, tyrosine, and serine residues. The phosphorylation process mediatedby the kinases regulates several physiological processes, while their overexpression resultsin the development of chronic diseases, including cancer. Targeting of receptor tyrosinekinase pathways results in the inhibition of angiogenesis and cell proliferation that validateskinases as a key target in the management of aggressive cancers. As such, the identificationof protein kinase inhibitors revolutionized the contemporary anticancer therapy byinducing a paradigm shift in the management of disease pathogenesis. Contemporary drugdesign programs focus on a broad range of kinase targets for the development of novelpharmacophores to manage the overexpression of kinases and their pathophysiology in cancerpathogenesis. In this review, we present the emerging trends in the development of rationallydesigned molecular inhibitors of kinases over the last five years (2016-2021) andtheir incipient role in the development of impending anticancer pharmaceuticals.
Purohit, M, Gupta, G, Afzal, O, Altamimi, ASA, Alzarea, SI, Kazmi, I, Almalki, WH, Gulati, M, Kaur, IP, Singh, SK & Dua, K 2023, 'Janus kinase/signal transducers and activator of transcription (JAK/STAT) and its role in Lung inflammatory disease', Chemico-Biological Interactions, vol. 371, pp. 110334-110334.
View/Download from: Publisher's site
Raj, A, Dua, K, Nair, RS, Sarath Chandran, C & Alex, AT 2023, 'Transethosome: An ultra-deformable ethanolic vesicle for enhanced transdermal drug delivery', Chemistry and Physics of Lipids, vol. 255, pp. 105315-105315.
View/Download from: Publisher's site
Rani, A, Devi Singh, V, Mazumder, R & Dua, K 2023, 'Cancer Proteomics for Cellular Dysfunction: Insights and Trends', Current Pharmaceutical Design, vol. 29, no. 9, pp. 697-712.
View/Download from: Publisher's site
View description>>
Background:Cancer is an ailment with having a very low survival rate globally. Poor cancer prognosisis primarily caused by the fact that people are found to have the disease when it is already well advanced.The goal of this study is to compile information on new avenues of investigation into biomarkers that may facilitatethe routine detection of cancer. Proteomic analysis has recently developed into a crucial technique for cancerbiology research, working in tandem with genomic analysis. Mass spectrometry techniques are one of severalproteome analysis techniques that allow for the highly precise quantitative and qualitative recognition of hundredsof proteins in small quantities from various biological materials. These findings might soon serve as thefoundation for better cancer diagnostic techniques.Methods:An exhaustive literature survey has been conducted using electronic databases such as Google Scholar,Science Direct, and PubMed with keywords of proteomics, applications of proteomics, the technology ofproteomics, biomarkers, and patents related to biomarkers.Result:Studies reported till 2021 focusing on cancer proteomics and the related patents have been included inthe present review to obtain concrete findings, highlighting the applications of proteomics in cancer.Conclusion:The present review aims to present the overview and insights into cancer proteomics, recent breakthroughsin proteomics techniques, and applications of proteomics with technological advancements, rangingfrom searching biomarkers to the characterization of molecular pathways, though the entire process is still in itsinfancy.
Rathore, C, Hemrajani, C, Sharma, AK, Gupta, PK, Jha, NK, Aljabali, AAA, Gupta, G, Singh, SK, Yang, J-C, Dwivedi, RP, Dua, K, Chellappan, DK, Negi, P & Tambuwala, MM 2023, 'Self-nanoemulsifying drug delivery system (SNEDDS) mediated improved oral bioavailability of thymoquinone: optimization, characterization, pharmacokinetic, and hepatotoxicity studies', Drug Delivery and Translational Research, vol. 13, no. 1, pp. 292-307.
View/Download from: Publisher's site
View description>>
AbstractThymoquinone (TQ) is an antioxidant, anti-inflammatory, and hepatoprotective compound obtained from the black seed oil of Nigella sativa. However, high hydrophobicity, instability at higher pH levels, photosensitivity, and low oral bioavailability hinder its delivery to the target tissues. A self-nanoemulsifying drug delivery system (SNEDDS) was fabricated using the microemulsification technique to address these issues. Its physicochemical properties, thermodynamic stability studies, drug release kinetics, in vivo pharmacokinetics, and hepatoprotective activity were evaluated. The droplet size was in the nano-range (< 90 nm). Zeta potential was measured to be −11.35 mV, signifying the high stability of the oil droplets. In vivo pharmacokinetic evaluation showed a fourfold increase in the bioavailability of TQ-SNEDDS over pure TQ. Furthermore, in a PCM-induced animal model, TQ-SNEDDS demonstrated significant (p < 0.05) hepatoprotective activity compared to pure TQ and silymarin. Reduction in liver biomarker enzymes and histopathological examinations of liver sections further supported the results. In this study, SNEDDS was demonstrated to be an improved oral delivery method for TQ, since it potentiates hepatotoxicity and enhances bioavailability. Graphical abstract
Rohilla, S, Singh, M, Alzarea, SI, Almalki, WH, Al-Abbasi, FA, Kazmi, I, Afzal, O, Altamimi, ASA, Singh, SK, Chellappan, DK, Dua, K & Gupta, G 2023, 'Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer', Journal of Environmental Pathology, Toxicology and Oncology, vol. 42, no. 1, pp. 27-50.
View/Download from: Publisher's site
Rohilla, S, Singh, M, Priya, S, Almalki, WH, Haniffa, SM, Subramaniyan, V, Fuloria, S, Fuloria, NK, Sekar, M, Singh, SK, Jha, NK, Chellappan, DK, Negi, P, Dua, K & Gupta, G 2023, 'Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin', Journal of Environmental Pathology, Toxicology and Oncology, vol. 42, no. 1, pp. 1-16.
View/Download from: Publisher's site
Ruiz-Lozano, F, Crespo-Sánchez, FE & Amador-Fernández, N 2023, 'Factores y estrategias en la implantación del Servicio de Indicación Farmacéutica en farmacia comunitaria', Farmacéuticos Comunitarios, vol. prepub, no. 1, pp. 13-16.
View/Download from: Publisher's site
Shaikh, MAJ, Afzal, O, almalki, WH, Kazmi, I, Alzarea, SI, Jafar, M, Alfawaz Altamimi, AS, Jakhmola, V, Anand, K, Singh, SK, Dua, K & Gupta, G 2023, 'Harnessing chitosan-adorned liposomes for enhanced drug delivery in cancer', Journal of Drug Delivery Science and Technology, vol. 85, pp. 104619-104619.
View/Download from: Publisher's site
Shaikh, MAJ, Gupta, G, Afzal, O, Gupta, MM, Goyal, A, Altamimi, ASA, Alzarea, SI, Almalki, WH, Kazmi, I, Negi, P, Singh, SK & Dua, K 2023, 'Sodium alginate-based drug delivery for diabetes management: A review', International Journal of Biological Macromolecules, vol. 236, pp. 123986-123986.
View/Download from: Publisher's site
View description>>
Diabetes mellitus (DM) is among the biggest global health problems of the 21st century, which is characterised by insufficient insulin secretion and results in the augmentation of blood sugar levels. The current foundation of hyperglycemia therapy is oral antihyperglycemic medications like biguanides, sulphonylureas, α-glucosidase inhibitors, peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, sodium-glucose co-transporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and others. Many naturally occurring substances have shown promise in treating hyperglycemia. Inadequate prologitivity of action, restricted bioavailability, site specificity, and dose-related side effects are some problems with currently available anti-diabetic medications. Sodium alginate has shown promise as a drug delivery mechanism, potentially solving issues with current therapies for several substances. This review summarizes the research on the efficacy of drug delivery systems based on alginate for transporting oral hypoglycemic medicines, phytochemicals, and insulin for treating hyperglycemia.
Sharma, A, Shambhwani, D, Pandey, S, Singh, J, Lalhlenmawia, H, Kumarasamy, M, Singh, SK, Chellappan, DK, Gupta, G, Prasher, P, Dua, K & Kumar, D 2023, 'Advances in Lung Cancer Treatment Using Nanomedicines', ACS Omega, vol. 8, no. 1, pp. 10-41.
View/Download from: Publisher's site
Sharma, D, Khan, H, Kumar, A, Grewal, AK, Dua, K & Singh, TG 2023, 'Pharmacological modulation of HIF-1 in the treatment of neuropsychiatric disorders', Journal of Neural Transmission, vol. 130, no. 12, pp. 1523-1535.
View/Download from: Publisher's site
Sharma, DS, Wadhwa, S, Gulati, M, Kumar, B, Chitranshi, N, Gupta, VK, Alrouji, M, Alhajlah, S, AlOmeir, O, Vishwas, S, Khursheed, R, Saini, S, Kumar, A, Parveen, SR, Gupta, G, Zacconi, F, Chellappan, DK, Morris, A, Loebenberg, R, Dua, K & Singh, SK 2023, 'Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: A new dimension to an anticancer drug', International Journal of Biological Macromolecules, vol. 224, pp. 810-830.
View/Download from: Publisher's site
Shrestha, J, Paudel, KR, Nazari, H, Dharwal, V, Bazaz, SR, Johansen, MD, Dua, K, Hansbro, PM & Warkiani, ME 2023, 'Advanced models for respiratory disease and drug studies', Medicinal Research Reviews, vol. 43, no. 5, pp. 1470-1503.
View/Download from: Publisher's site
View description>>
AbstractThe global burden of respiratory diseases is enormous, with many millions of people suffering and dying prematurely every year. The global COVID‐19 pandemic witnessed recently, along with increased air pollution and wildfire events, increases the urgency of identifying the most effective therapeutic measures to combat these diseases even further. Despite increasing expenditure and extensive collaborative efforts to identify and develop the most effective and safe treatments, the failure rates of drugs evaluated in human clinical trials are high. To reverse these trends and minimize the cost of drug development, ineffective drug candidates must be eliminated as early as possible by employing new, efficient, and accurate preclinical screening approaches. Animal models have been the mainstay of pulmonary research as they recapitulate the complex physiological processes, Multiorgan interplay, disease phenotypes of disease, and the pharmacokinetic behavior of drugs. Recently, the use of advanced culture technologies such as organoids and lung‐on‐a‐chip models has gained increasing attention because of their potential to reproduce human diseased states and physiology, with clinically relevant responses to drugs and toxins. This review provides an overview of different animal models for studying respiratory diseases and evaluating drugs. We also highlight recent progress in cell culture technologies to advance integrated models and discuss current challenges and present future perspectives.
Singh, M, Kumar, R, Sharma, S, Kumar, L, Kumar, S, Gupta, G, Dua, K & Kumar, D 2023, 'Hedychium spicatum: A comprehensive insight into its ethnobotany, phytochemistry, pharmacological and therapeutic attributes', South African Journal of Botany, vol. 161, pp. 638-647.
View/Download from: Publisher's site
Singh, N, Vishwas, S, Kaur, A, Kaur, H, Kakoty, V, Khursheed, R, Chaitanya, MVNL, Babu, MR, Awasthi, A, corrie, L, Harish, V, Yanadaiah, P, Gupta, S, Sayed, AA, El-Sayed, A, Ali, I, Kensara, OA, Ghaboura, N, Gupta, G, Dou, AM, Algahtani, M, El-kott, AF, Dua, K, Singh, SK & Abdel-Daim, MM 2023, 'Harnessing role of sesamol and its nanoformulations against neurodegenerative diseases', Biomedicine & Pharmacotherapy, vol. 167, pp. 115512-115512.
View/Download from: Publisher's site
Singh, SK, Thakur, K, Sharma, V, Saini, M, Sharma, D, Vishwas, S, Kakoty, V, Pal, RS, Chaitanya, MVNL, Babu, MR, Gupta, S, Rehman, ZU, Smriti, Singla, M, Gupta, G, Jakhmola, V, Pinto, TDJA, Kumbhar, P, Disouza, J, Patravale, V, Dua, K & Gadewar, MM 2023, 'Exploring the multifaceted potential of chlorogenic acid: Journey from nutraceutical to nanomedicine', South African Journal of Botany, vol. 159, pp. 658-677.
View/Download from: Publisher's site
Smit, CCH, Rogers, K, Robertson, H, Taxis, K & Pont, LG 2023, 'Real-World Data about Commonly Used Antibiotics in Long-Term Care Homes in Australia from 2016 to 2019', Antibiotics, vol. 12, no. 9, pp. 1393-1393.
View/Download from: Publisher's site
View description>>
In this study, we use real-world data to explore trends in antibiotic use in a dynamic cohort of long-term care (LTC) residents. A cross-sectional retrospective analysis of pharmacy medication supply records of 3459 LTC residents was conducted from 31 May 2016 to 31 May 2019. The primary outcome was the monthly prevalence of residents with an antibiotic episode. Secondary outcomes were the type of antibiotic used and duration of use. Over the three-year study period, residents were supplied 10460 antibiotics. On average, 18.9% of residents received an antibiotic monthly. Antibiotic use decreased slightly over time with a mean of 168/1000 (95% CI 146–177) residents using at least one antibiotic per month in June 2016 to 148/1000 (95% CI 127–156) in May 2019. The total number of antibiotic days per 100 resident days remained relatively constant over the study period: 8.8 days in 2016–2017, 8.4 in 2017–2018 and 6.4 in 2018–2019. Prolonged durations exceeding 100 days were seen for a small percentage of residents. We found extensive antibiotic use, which is a recognized contributor to antimicrobial resistance development, underscoring the necessity for quality treatment guidelines in this vulnerable population.
Steel, A, Foley, H, Bugarcic, A, Wardle, J, Boyd, H, Breakspear, I, Carlton, A-L, Cope, G, Dua, K, Greenway, P, Redmond, R, Hawrelak, J, Shukla, N & Adams, J 2023, 'Exploring Criteria for the Translation of Traditional Knowledge Within Contemporary Clinical Practice, Research, Policy, and Education: A Stakeholder Forum', Journal of Integrative and Complementary Medicine, vol. 29, no. 6-7, pp. 348-360.
View/Download from: Publisher's site
View description>>
Background: The 2018 Declaration of Astana identifies traditional knowledge (TK) as one of the drivers for strengthening primary health care systems through the use of technology (traditional medicines) and knowledge and capacity building (traditional practitioners). While TK underpins both traditional practice and the use of traditional medicines, facilitating the use of TK in contemporary health care systems has been difficult to achieve. The aim of this study was to identify key factors related to the translation of TK into contemporary settings to help establish tools to support the knowledge translation process. Methods: This study used World Café methodology to collect the observations, ideas, and perspectives of experts who use TK in their practice. These experts (n = 9) were from a variety of contexts, including clinical practice, research, education, policy, and consumer advocacy, participated in the 1-day event. Data were collected into NVivo 12 software and analyzed using inductive-deductive thematic analysis. Results: Thematic analysis identified five themes: the need to define the elements required for critical evaluation of sources of TK as evidence, the importance of applying a tradition-centric lens when translating TK for contemporary use, the need to bridge gaps between TK and its contemporary applications, the value of critically evaluating the TK translation process itself, and the recognition of traditions as living systems. Taken together, the themes showed holistic interpretation of the translation process that incorporates critical analysis of the TK itself and accountable, transparent, and ethical processes of translation that consider safety, socioeconomical and intellectual property impacts of TK in contemporary use. Conclusions: Stakeholders identified TK as a valid and important source of evidence that should guide practice in a range of contemporary settings (e.g., policy and clinical practice), and outlined important consi...
Thapa, K, Shivam, K, Khan, H, Kaur, A, Dua, K, Singh, S & Singh, TG 2023, 'Emerging Targets for Modulation of Immune Response and Inflammation in Stroke', Neurochemical Research, vol. 48, no. 6, pp. 1663-1690.
View/Download from: Publisher's site
Thapa, R, Afzal, O, Alfawaz Altamimi, AS, Goyal, A, Almalki, WH, Alzarea, SI, Kazmi, I, Jakhmola, V, Singh, SK, Dua, K, Gilhotra, R & Gupta, G 2023, 'Galangin as an inflammatory response modulator: An updated overview and therapeutic potential', Chemico-Biological Interactions, vol. 378, pp. 110482-110482.
View/Download from: Publisher's site
Thapa, R, Afzal, O, Bhat, AA, Goyal, A, Alfawaz Altamimi, AS, Almalki, WH, Alzarea, SI, Kazmi, I, Singh, SK, Dua, K, Thangavelu, L & Gupta, G 2023, 'New Horizons in Lung Cancer Management Through ATR/CHK1 Pathway Modulation', Future Medicinal Chemistry, vol. 15, no. 19, pp. 1807-1818.
View/Download from: Publisher's site
View description>>
Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling has contributed to a new classification of lung cancer, driving advancements in research and therapy. The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway plays a crucial role in maintaining genomic stability, and its activation has been linked to the development of lung cancer, drug resistance and poor prognosis. Clinical and preclinical studies have demonstrated promising results in targeting this pathway. ATR and CHK1 are proteins that collaborate to repair DNA damage caused by radiation or chemotherapy. ATR/CHK1 inhibitors are currently under investigation in preclinical and clinical trials. This article explores the ATR/CHK1 pathway and its potential for treating lung cancer.
Thapa, R, Afzal, O, Gupta, G, Bhat, AA, Almalki, WH, Alzarea, SI, Kazmi, I, Altamimi, ASA, Subramaniyan, V, Thangavelu, L, Singh, SK & Dua, K 2023, 'Unveiling the connection: Long-chain non-coding RNAs and critical signaling pathways in breast cancer', Pathology - Research and Practice, vol. 249, pp. 154736-154736.
View/Download from: Publisher's site
Thapa, R, Ali, H, Afzal, O, Ahmad Bhat, A, Hassan Almalki, W, Alzarea, SI, Kazmi, I, Saleh Alfawaz Altamimi, A, Jain, N, Pandey, M, Kumar Fuloria, N, Sekar, M, Unnikrishnan Meenakshi, D, Jakhmola, V, Kumar Singh, S, Dua, K & Gupta, G 2023, 'Correction to: Unlocking the potential of mesoporous silica nanoparticles in breast cancer treatment', Journal of Nanoparticle Research, vol. 25, no. 9, p. 187.
View/Download from: Publisher's site
Thapa, R, Ali, H, Afzal, O, Bhat, AA, Almalki, WH, Alzarea, SI, Kazmi, I, Altamimi, ASA, Jain, N, Pandey, M, Fuloria, NK, Sekar, M, Meenakshi, DU, Jakhmola, V, Singh, SK, Dua, K & Gupta, G 2023, 'Unlocking the potential of mesoporous silica nanoparticles in breast cancer treatment', Journal of Nanoparticle Research, vol. 25, no. 8.
View/Download from: Publisher's site
Thapa, R, Gupta, G, Bhat, AA, Almalki, WH, Alzarea, SI, Kazmi, I, Saleem, S, Khan, R, Altwaijry, N, Dureja, H, Singh, SK & Dua, K 2023, 'A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies', International Journal of Biological Macromolecules, vol. 253, pp. 127375-127375.
View/Download from: Publisher's site
Unnisa, A, Dua, K & Kamal, MA 2023, 'Mechanism of Mesenchymal Stem Cells as a Multitarget Disease-Modifying Therapy for Parkinson's Disease', Current Neuropharmacology, vol. 21, no. 4, pp. 988-1000.
View/Download from: Publisher's site
View description>>
Abstract:Parkinson’s disease (PD) is one of the most prevalent neurodegenerative disorders, affectingthe basal nuclei, causing impairment of motor and cognitive functions. Loss of dopaminergic(DAergic) neurons or their degeneration and the aggregation of Lewy bodies is the hallmark of thisdisease. The medications used to treat PD relieve the symptoms and maintain quality of life, but currently,there is no cure. There is a need for the development of therapies that can cease or perhapsreverse neurodegeneration effectively. With the rapid advancements in cell replacement therapytechniques, medical professionals are trying to find a cure by which restoration of dopamine neurotransmitterscan occur. Researchers have started focusing on cell-based therapies using mesenchymalstem cells (MSCs) due to their abundance in the body, the ability of proliferation, and immunomodulation.Here we review the MSC-based treatment in Parkinson's disease and the variousmechanisms it repairs DAergic neurons in parkinsonian patients.
Vikash, B, Shashi, Pandey, NK, Kumar, B, Wadhwa, S, Goutam, U, Alam, A, Al-Otaibi, F, Chaubey, P, Mustafa, G, Gupta, G, Dua, K & Singh, SK 2023, 'Formulation and evaluation of ocular self-nanoemulsifying drug delivery system of brimonidine tartrate', Journal of Drug Delivery Science and Technology, vol. 81, pp. 104226-104226.
View/Download from: Publisher's site
Vishwas, S, Kumar, R, Khursheed, R, Ramanunny, AK, Kumar, R, Awasthi, A, Corrie, L, Porwal, O, Arshad, MF, Alshammari, MK, Alghitran, AA, Qumayri, AN, Alkhaldi, SM, Alshammari, AK, Chellappan, DK, Gupta, G, Collet, T, Adams, J, Dua, K, Gulati, M & Singh, SK 2023, 'Expanding Arsenal against Neurodegenerative Diseases Using QuercetinBased Nanoformulations: Breakthroughs and Bottlenecks', Current Neuropharmacology, vol. 21, no. 7, pp. 1558-1574.
View/Download from: Publisher's site
View description>>
Abstract:Quercetin (Qu), a dietary flavonoid, is obtained from many fruits and vegetables such ascoriander, broccoli, capers, asparagus, onion, figs, radish leaves, cranberry, walnuts, and citrusfruits. It has proven its role as a nutraceutical owing to numerous pharmacological effects againstvarious diseases in preclinical studies. Despite these facts, Qu and its nanoparticles are less exploredin clinical research as a nutraceutical. The present review covers various neuroprotective actions ofQu against various neurodegenerative diseases (NDs) such as Alzheimer’s, Parkinson’s, Huntington’s,and Amyotrophic lateral sclerosis. A literature search was conducted to systematically reviewthe various mechanistic pathways through which Qu elicits its neuroprotective actions and the challengesassociated with raw Qu that compromise therapeutic efficacy. The nanoformulations developedto enhance Qu’s therapeutic efficacy are also covered. Various ongoing/completed clinical trialsrelated to Qu in treating various diseases, including NDs, are also tabulated. Despite these manysuccesses, the exploration of research on Qu-loaded nanoformulations is limited mostly to preclinicalstudies, probably due to poor drug loading and stability of the formulation, time-consumingsteps involved in the formulation, and their poor scale-up capacity. Hence, future efforts are requiredin this area to reach Qu nanoformulations to the clinical level.
